Lantern Pharma Debt-to-Equity Ratio Growth & History (LTRN)

Lantern Pharma's debt-to-equity ratio was 0.01 for fiscal 2025.

View full Lantern Pharma company overview

Lantern Pharma annual debt-to-equity ratio history

Lantern Pharma annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20252025-12-310.010.00+4.52%
20242024-12-310.010.01+100.64%
20232023-12-310.010.00+507.28%
20222022-12-310.00−0.00−67.04%
20212021-12-310.00

Lantern Pharma debt-to-equity ratio trends

Between the periods ended 2021-12-31 and 2025-12-31, Lantern Pharma's debt-to-equity ratio increased from 0.00 to 0.01, a change of 0.01. The latest reported quarter, Q1 2026, shows 0.02.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Lantern Pharma source filings ↗

Community posts

It’s quiet here.

No posts about LTRN yet. Start the conversation.

Write the first post